INDP Stock Price, Chart, Stats & News
Indaptus Therapeutics, Inc. (INDP) does not currently pay a dividend.
INDP chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -223.94% |
ROE | -938.75% |
D/E | – |
Interest coverage ratio | – |
INDP valuation
P/E | – |
P/S | – |
P/B | 1.22x |
P/CF | -0.25x |
P/FCF | -0.20x |
P/OCF | -0.25x |
PEG | 0.01x |
EV multiple | -0.56x |
About
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus.
Similar securities
Based on sector and market capitalization
